Previous 10 | Next 10 |
RESEARCH TRIANGLE PARK, N.C., Nov. 26, 2019 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a clinical-stage oncology company, today announced that Chief Executive Officer Mark Velleca, M.D., Ph.D. will participate in a fireside chat at the Evercore ISI 2 nd Annual HealthCONx Con...
The following slide deck was published by G1 Therapeutics, Inc. in conjunction with this Read more ...
RESEARCH TRIANGLE PARK, N.C., Nov. 12, 2019 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a clinical-stage oncology company, today announced that Chief Executive Officer Mark Velleca, M.D., Ph.D. will present a company overview at the Stifel Healthcare Conference. The pres...
G1 Therapeutics, Inc. (GTHX) Q3 2019 Earnings Conference Call November 05, 2019, 16:30 ET Company Participants Jeff Macdonald - Head, Investor & Public Relations Mark Velleca - CEO, President & Director Rajesh Malik - Chief Medical Officer and SVP, R&D Jennifer Mose...
Image source: The Motley Fool. G1 Therapeutics, Inc. (NASDAQ: GTHX) Q3 2019 Earnings Call Nov 5, 2019 , 4:30 p.m. ET Operator Continue reading
G1 Therapeutics (NASDAQ: GTHX ): Q3 GAAP EPS of -$0.86 misses by $0.01 . More news on: G1 Therapeutics, Inc., Earnings news and commentary, Healthcare stocks news, Read more ...
Company to complete New Drug Application (NDA) submission for trilaciclib in small cell lung cancer in 2Q20 Phase 2 trilaciclib data and Phase 1 G1T48 data presented at ESMO Management to host webcast and conference call today at 4:30 p.m. ET RESEARCH TRIANGLE PARK, N.C., Nov....
RESEARCH TRIANGLE PARK, N.C., Oct. 29, 2019 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a clinical-stage oncology company, today announced that it will host a webcast and conference call to provide a corporate and financial update for the third quarter of 2019 on Tuesday, Nove...
Over the past month, lots of biotech stocks have been hammered for reasons that aren't always clear. The market has made mistakes in the past and investors are right to assume it may have gone too far with some of these unfortunate companies. Can any of these beaten-down drugmakers bounce back?...
Shares of G1 Therapeutics (NASDAQ: GTHX) fell 37.2% in September, according to data from S&P Global Market Intelligence , after investors reacted to trial data for some of the biopharmaceutical company's cancer drug candidates. To be sure, shares plunged 33% on Monday, Se...
News, Short Squeeze, Breakout and More Instantly...
Enact Holdings Inc. (ACT) is expected to report $0.99 for Q1 2024 FormFactor Inc. (FORM) is expected to report $0.09 for Q1 2024 SAAB AB - Class B (SAABF) is expected to report for quarter end 2024-03-31 Lumos Pharma Inc. (LUMO) is expected to report $-1.21 for Q1 2024 Axis Capita...
- Achieved $14.1 Million in Net Revenue from Sales of COSELA® (trilaciclib) for First Quarter 2024 - - Reaffirmed 2024 Net COSELA Revenue Guidance of $60 to $70 Million - - Announced That Updated Efficacy Results from Phase 2 Trial of Trilaciclib in Combination with a TROP2 Antibod...
RESEARCH TRIANGLE PARK, N.C. and BOSTON, May 01, 2024 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX ), a commercial-stage oncology company, and Pepper Bio, the world’s first transomics drug discovery and development company, announced a global licensing agreement (excluding t...